Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSTiplaxtinin is an inhibitor of plasminogen activator inhibitor 1 (PAI-1; IC50 = 2.7 µM for the human enzyme).1 It inhibits differentiation of human adipocytes when used at a concentration of 5 µM.2 Tiplaxtinin (5 and 20 mg/kg) reduces tumor growth and microvessel density in a T24 bladder cancer mouse xenograft model.3 It prevents carotid artery occlusion, increases the time to occlusive thrombosis, and decreases the thrombus size in a rat model of ferric chloride-induced arterial thrombosis when administered at a dose of 1 mg/kg.4
WARNING This product is not for human or veterinary use.
1. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-
2. Modulation of adipose tissue development by pharmacological inhibition of PAI-
3. Targeting plasminogen activator inhibitor-
4. Effect of tiplaxtinin (PAI-